Results of the study, which were released in the Journal of Oncology Practice, found that:

• Patients who received precision cancer medicine experienced an improved progression-free survival of 22.9 weeks, compared with 12 weeks for patients receiving standard treatments.
• Survival rates were not associated with increased medical costs:  In an analysis of patients who received all care within the Intermountain Healthcare system, patient charges were actually less in the precision treatment group than the control group. 

Seventy-two patients with metastatic cancer of diverse subtypes were treated in the setting of a large, integrated healthcare delivery system between July 1, 2013 and January 31, 2015. 

Find the full study, A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Costs.